12 citations
,
June 2025 in “Gut Microbes” This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.
1 citations
,
December 2022 in “Plants” This study suggests that CSLD1 is key to nitrogen-dependent root hair elongation and regulation of AMT1;2 expression in rice roots.
In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.
August 2017 in “Seoul National University Open Repository (Seoul National University)” The study investigated the role of Aminoacyl-tRNA synthetase interacting multifunctional protein 1 (AIMP1) in hair follicle stem cell proliferation and its potential as a treatment for alopecia. AIMP1, when dissociated from the multi-tRNA synthetase complex, was found to be secreted by dermal papilla cells in a sonic hedgehog (Shh) signal-dependent manner. This secretion increased the proliferation of CD34+ hair follicle stem cells by promoting the wnt signaling pathway through inhibition of sFRP1, a known wnt antagonist. The research demonstrated that the N-terminal fragment of AIMP1 could be developed into a therapeutic peptide for hair loss. When applied topically to depilated mice, this peptide significantly accelerated hair growth, especially when formulated with carbomer. The findings highlighted a novel mechanism of AIMP1 action and its potential application in alopecia treatment.
4 citations
,
January 2025 in “Dermatologica Sinica” This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.
April 2025 in “Sabuncuoglu Serefeddin Health Sciences” This study highlights the public health significance of androgenic-anabolic steroid use disorder, emphasizing health risks, societal effects, and the need for routine AAS analyses in forensic autopsies, especially in athlete deaths.
November 2025 in “Scientific Reports” This study demonstrates that an AI-based grading framework using a novel area ratio metric improves the accuracy and consistency of male pattern hair loss classification, especially in advanced grades, compared to traditional methods.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.
November 2023 in “Research Portal Denmark” This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.
1 citations
,
January 2026 in “Frontiers in Cell and Developmental Biology” This study reviews the transformative role of artificial intelligence in biomaterial design, highlighting its ability to reduce costs through virtual screening, enhance material performance, and predict biological interactions to advance personalized and precision medicine.
August 2024 in “Clinical and Experimental Dermatology” This study found that while DALL-E 2 can create realistic hair images from text prompts, its accuracy in depicting specific hair disorders, like alopecia areata, often falls short, highlighting the need for AI developers to work with medical experts to improve dermatological applications.
3 citations
,
May 2025 in “Carbohydrate Polymers” In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.
May 2026 in “BMC Medicine” This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.
April 2023 in “Clinical Chemistry and Laboratory Medicine” The document concludes that inflammation markers can be used in diabetes, vitamin D3 affects immune pathways, hyperthyroidism changes hormone levels, androgen levels help diagnose Adrenocortical Carcinoma, erectile dysfunction is linked to diabetes, hypogonadism is common in HIV-infected males, and hormones can be biomarkers for various conditions.
June 2023 in “Dermatology and therapy” This study found that most dermatologists in the Middle East manage mild to severe alopecia areata primarily with potent topical corticosteroids and identified long-term disease control and improved efficacy as key unmet needs.
August 2019 in “Carolina Digital Repository (University of North Carolina at Chapel Hill)” This study indicates that MAGE-11 modulates androgen receptor transcriptional activity through F-box interactions, independent of the activation function 2 pathway, revealing a novel mechanism for androgen receptor regulation.
July 2026 in “Journal of the American Academy of Dermatology” 
2 citations
,
October 2003 in “Australian Prescriber” This article describes the Australian Medicines Handbook as a compact, readable, and comprehensive drug reference guide for Australian practitioners, but it does not present new research findings.
January 2026 in “Biomedicines” This study identified increased expression of ACAA1 and its regulation by hsa-miR-1343-3p, linking androgenetic alopecia to lipid metabolism pathways, particularly through PPAR signaling, in scalp tissues.
4 citations
,
July 2024 in “The Journal of Dermatology” This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.
This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.
October 2020 in “The American journal of gastroenterology” This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.
This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.
September 2025 in “Dermatology and Therapy” This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
This study introduces diagnostic and therapeutic algorithms tailored for tailored management of alopecia areata based on patient-specific factors like age, disease severity, and quality of life.
In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.
October 2024 in “Canadian Journal of Health Technologies” This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.
January 1995 in “Adolescent and pediatric gynecology” This article reviews genetic and phenotypic aspects of androgen insensitivity syndromes, emphasizing the diversity of mutations that complicates molecular screening and the importance of genotype-phenotype correlations.